1. Home
  2. VERA vs DKL Comparison

VERA vs DKL Comparison

Compare VERA & DKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VERA
  • DKL
  • Stock Information
  • Founded
  • VERA 2016
  • DKL 2012
  • Country
  • VERA United States
  • DKL United States
  • Employees
  • VERA N/A
  • DKL N/A
  • Industry
  • VERA Biotechnology: Pharmaceutical Preparations
  • DKL Natural Gas Distribution
  • Sector
  • VERA Health Care
  • DKL Energy
  • Exchange
  • VERA Nasdaq
  • DKL Nasdaq
  • Market Cap
  • VERA 2.0B
  • DKL 2.3B
  • IPO Year
  • VERA 2021
  • DKL N/A
  • Fundamental
  • Price
  • VERA $24.00
  • DKL $43.74
  • Analyst Decision
  • VERA Buy
  • DKL Buy
  • Analyst Count
  • VERA 8
  • DKL 4
  • Target Price
  • VERA $64.63
  • DKL $44.25
  • AVG Volume (30 Days)
  • VERA 2.3M
  • DKL 96.4K
  • Earning Date
  • VERA 08-07-2025
  • DKL 08-05-2025
  • Dividend Yield
  • VERA N/A
  • DKL 10.15%
  • EPS Growth
  • VERA N/A
  • DKL 7.97
  • EPS
  • VERA N/A
  • DKL 2.98
  • Revenue
  • VERA N/A
  • DKL $938,491,000.00
  • Revenue This Year
  • VERA N/A
  • DKL $21.19
  • Revenue Next Year
  • VERA N/A
  • DKL N/A
  • P/E Ratio
  • VERA N/A
  • DKL $14.67
  • Revenue Growth
  • VERA N/A
  • DKL N/A
  • 52 Week Low
  • VERA $18.53
  • DKL $34.59
  • 52 Week High
  • VERA $51.61
  • DKL $45.71
  • Technical
  • Relative Strength Index (RSI)
  • VERA 54.33
  • DKL 61.82
  • Support Level
  • VERA $22.76
  • DKL $42.29
  • Resistance Level
  • VERA $23.97
  • DKL $43.83
  • Average True Range (ATR)
  • VERA 1.21
  • DKL 0.91
  • MACD
  • VERA 0.15
  • DKL -0.05
  • Stochastic Oscillator
  • VERA 73.63
  • DKL 81.31

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

About DKL Delek Logistics Partners L.P. Common Units representing Limited Partner Interests

Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.

Share on Social Networks: